glp-1 weight loss drugs tirzepatide semaglutide vs. Semaglutide: Which Medication is Right for You? Tirzepatide vs Semaglutide for Weight

Summary Integrating emerging mechanistic and clinical observations, this review synthesizes current evidence from a metabolic flux perspective

Liraglutide (3.0 mg, daily subcutaneous injection, n=22) or semaglutide (1.0 mg, weekly subcutaneous injection, n=18) was started 74.5 (51.0, 108.3) months after surgery following a weight regain of 14.7 (10.3, 19.6)%

Discover the research, how they work, who should try these, and more.

Recent phase 2 and phase 3 clinical trials have established the therapeutic value of various GLP-1 RAs in improving liver histology and metabolic parameters in patients with MASH

Researchers are examining whether drugs currently approved to treat obesity and type 2 diabetes could be useful for a wider range of health challenges.